pimobendan has been researched along with Cardiac Failure in 105 studies
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "The benefits of pimobendan in the treatment of congestive heart failure (CHF) in cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively." | 9.41 | Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. ( Glaus, T; Lehmkuhl, L; Loureiro, J; Luis Fuentes, V; MacGregor, J; Mohren, N; Rush, JE; Sayer, MP; Schober, KE; Summerfield, NJ; Wess, G; Wright, K, 2021) |
| "A fixed-dose combination tablet of benazepril and pimobendan (Fortekor Plus; Elanco Animal Health) was tested in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD) in a three-arm, masked, randomized, non-inferiority clinical trial in Japan." | 9.27 | Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial. ( Forster, S; Hirakawa, A; King, JN; Otaki, H; Sakakibara, N; Seewald, W; Sonobe, J, 2018) |
| "Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD)." | 9.22 | Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2016) |
| "No significant difference between pimobendan and placebo was found on incidence of supraventricular or ventricular arrhythmia." | 9.20 | Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. ( Griffiths, LG; Kass, PH; Lake-Bakaar, GA; Singh, MK, 2015) |
| "To evaluate the clinical efficacy and safety of pimobendan by comparing it with ramipril over a six-month period in dogs with mild to moderate heart failure (HF) caused by myxomatous mitral valve disease (MMVD)." | 9.11 | Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. ( Corcoran, BM; Dukes-McEwan, J; French, AT; Lee, AJ; Smith, PJ; Smith, SG; Swift, ST; Van Israël, N, 2005) |
| "The long-term beneficial effects of pimobendan in the treatment of chronic heart failure (CHF) have not been established, so the present trial compared pimobendan (1." | 9.10 | Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). ( , 2002) |
| "To evaluate the effects of the addition of pimobendan to an optimal basic regimen on plasma levels of neurohumoral factors in patients with non-ischemic, moderate heart failure during 2-year follow-up." | 9.09 | Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure. ( Komamura, K; Kubo, T; Nishikimi, T; Sasaki, T, 1999) |
| "Pimobendan improves exercise capacity in patients with chronic heart failure who are also on conventional treatment." | 9.08 | Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. ( Dumont, JM; Heinrich-Nols, J; Hjalmarsson, AC; Just, H; La Framboise, D; Lubsen, J; Remme, WJ; Seed, P, 1996) |
| "The results of Japanese studies on the clinical efficacy and safety of pimobendan in the treatment of heart failure are summarized in this paper." | 9.08 | Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan. ( Kato, K, 1997) |
| "The effects of pimobendan (UD-CG 115) on hemodynamics and exercise capacity after acute (single dose) and chronic (6 month) oral treatment, as well as acute treatment after 6 months were investigated in 67 patients with chronic heart failure of NYHA classes II or III, which had persisted in spite of treatment with diuretics and digitalis." | 9.07 | [Acute and long-term effects of pimobendan (UD-CG 115) in NYHA II and III heart failure. Results of a randomized multicenter double-blind study]. ( Assmann, I; Duck, HG; Fiehring, H; Höfs, T; Kassel, P; Morgan, P; Nehmiz, G; Schmidt, PK, 1991) |
| "Acute hemodynamics of pimobendan were compared to captopril in a crossover trial in patients with chronic heart failure (NYHA II-III)." | 9.07 | Acute hemodynamics of pimobendan in chronic heart failure. A comparative crossover study of captopril and pimobendan. ( Aizaki, T; Hanawa, H; Izumi, T; Kodama, M; Kuwano, H; Shibata, A; Suzuki, M; Takahashi, M; Tsuda, T; Uchiyama, H, 1992) |
| "These data demonstrate that pimobendan significantly increases exercise duration, peak VO2, and quality of life in patients with heart failure." | 9.07 | Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. ( Bourge, R; Brodsky, M; Brozena, S; Cobb, F; Gollub, S; Jessup, M; Kirlin, P; Kubo, SH; Rahko, P; Shanes, J, 1992) |
| "To determine the reliability and validity of a patient outcome questionnaire for chronic heart failure, a randomized, double-blind, placebo-controlled, 3-month trial of pimobendan, an investigational medication with inotropic and vasodilator activities, was performed." | 9.07 | Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. ( Cohn, JN; Rector, TS, 1992) |
| "In view of growing scepticism as to the efficacy and safety of agents with predominant phosphodiesterase inhibiting properties in heart failure, the clinical efficacy and safety of pimobendan, a calcium-sensitizing and partially phosphodiesterase-inhibiting compound, was compared with enalapril in 242 patients with mild to moderate heart failure (NYHA classification II-III) despite diuretics and digitalis, and abnormal haemodynamics at baseline." | 9.07 | Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group. ( Baiker, W; Baumann, G; Frick, MH; Haehl, M; Krayenbühl, HP; Nehmiz, G; Remme, WJ, 1994) |
| "In contrast to cyclic AMP-dependent positive inotropes, the calcium-sensitizer and partial phosphodiesterase (PDE) inhibitor pimobendan may induce beneficial effects in heart failure." | 9.07 | Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. ( Bartels, GL; de Leeuw, PW; Krauss, XH; Kruijssen, DA; Remme, WJ; Storm, CJ; van Hoogenhuyze, DC, 1994) |
| "The long-term efficacy of the positive inotropic and vasodilator drug, pimobendan, was assessed in 21 patients suffering from symptomatic heart failure." | 9.07 | Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. ( Asanoi, H; Ejiri, M; Horikoshi, I; Kihara, Y; Sasayama, S; Terada, Y; Yokawa, S; Yoshida, S, 1994) |
| "In 25 patients whose chronic congestive heart failure (CHF) had recently worsened to New York Heart Association class IV, pimobendan (5 to 20 mg/day) was added to maximum conventional therapy consisting of digoxin, diuretics, angiotensin-converting enzyme inhibitors, coumadin derivatives to prevent thromboembolic complications, and amiodarone to suppress serious ventricular rhythm disturbances." | 9.07 | Intractable heart failure despite angiotensin-converting enzyme inhibitors, digoxin, and diuretics: long-term effectiveness of add-on therapy with pimobendan. ( Hagemeijer, F, 1991) |
| " We compared the effects of two doses (5 and 10 mg) of oral pimobendane (UD-CG 115) on haemodynamics in eight patients suffering from chronic congestive heart failure." | 9.06 | Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses. ( Bernard, R; Dresse, A; Goethals, H; Liebens, I; Renard, M; Walter, M, 1988) |
| "Pimobendan is an oral inodilator compound available in many countries for use in canine heart failure." | 8.82 | Use of pimobendan in the management of heart failure. ( Fuentes, VL, 2004) |
| "The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD)." | 7.85 | Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure. ( Chimura, S; Endo, M; Harada, K; Hirakawa, A; Maetani, S; Mizukoshi, T; Mizuno, M; Mizuno, T; Sawada, T; Shinoda, A; Takahashi, A; Takeuchi, J; Takusagawa, Y; Uchida, S; Uechi, M; Yamano, S, 2017) |
| "We evaluated the effect of pimobendan, a positive inotropic agent, in elderly patients with frequent readmission as a result of heart failure despite conventional therapy." | 7.80 | Effect of pimobendan in addition to standard therapy for heart failure on prevention of readmission in elderly patients with severe chronic heart failure. ( Arakawa, S; Hayano, M; Kawano, H; Maemura, K; Matsumoto, Y; Nakatomi, D; Satoh, O; Yamasa, T, 2014) |
| "To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM)." | 7.80 | Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. ( Ames, MK; Atkins, CE; DeFrancesco, TC; Hodge, TE; Keene, BW; Meurs, KM; Reina-Doreste, Y; Stern, JA; Tou, SP, 2014) |
| "27 client-owned cats (16 male and 11 female) with heart failure, treated with pimobendan (mean ± SD dosage, 0." | 7.78 | Effect of oral administration of pimobendan in cats with heart failure. ( Achen, SE; Boggess, MM; Drourr, L; Fries, RC; Gordon, SG; Hariu, CD; Miller, MW; Roland, RM; Saunders, AB; Winter, RL, 2012) |
| " Using 6 conscious dogs with tachycardia-induced heart failure, the FFR was examined before and after administration of dobutamine (6 microg/kg/min) or pimobendan (0." | 7.71 | Disparate force-frequency effects of pimobendan and dobutamine in conscious dogs with tachycardia-induced cardiomyopathy. ( Asanoi, H; Inoue, H; Ishizaka, S; Joho, S; Kameyama, T, 2002) |
| "Pharmacokinetics and pharmacodynamics of pimobendan were studied in eight patients with dilated cardiomyopathy and chronic congestive heart failure after single dosing and after 2-week repeated dosing of 5 mg racemic pimobendan." | 7.69 | Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing. ( Chu, KM; Hu, OY; Shieh, SM, 1995) |
| "We studied the effects of oral administration of pimobendane on hemodynamics, blood gas levels, the renin-angiotensin system, and plasma catecholamines in 11 patients who were affected by severe chronic congestive heart failure." | 7.67 | Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent. ( Bernard, R; Dresse, A; Liebens, I; Renard, M; Walter, M, 1988) |
| "Pimobendan (UD-CG 115 BS) was administered orally to 23 patients with congestive heart failure (functional class IV) caused by coronary artery disease (11 patients) or idiopathic dilated cardiomyopathy (12)." | 7.67 | Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Brand, HJ; Hagemeijer, F; van Mechelen, R, 1989) |
| "Pimobendan (10 mg on day 1, then 5 mg twice daily for 28 days) was administered orally to nine patients in class III-IV stable congestive heart failure." | 7.67 | Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing. ( Brand, HJ; Hagemeijer, F; Roth, W, 1989) |
| "The acute systemic hemodynamic effects of the calcium antagonist nisoldipine and the pyridazinone-derivative pimobendan, a phosphodiesterase inhibitor with vasodilating as well as positive inotropic properties, were studied in conscious pigs with chronic heart failure." | 7.67 | Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure. ( Duncker, DJ; Roelandt, JR; van der Giessen, WJ; van Woerkens, LJ; Verdouw, PD, 1989) |
| "Pimobendan was administered orally (10 mg single dose on day 1, then 5 mg twice daily for 4 weeks) to nine patients with chronic heart failure undergoing hemodynamic monitoring." | 7.67 | Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure. ( Brand, HJ; Hagemeijer, F; Roth, W, 1989) |
| "Pimobendan is a positive inotropic agent with additional calcium-sensitizing effects of the phosphodiesterase III-inhibitor group." | 6.67 | [Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure]. ( Bergler-Klein, J; Globits, S; Glogar, D; Mayr, H; Porenta, G; Sochor, H; Stefenelli, T, 1992) |
| "Pimobendan is a benzimidazole-pyridazinone derivative with calcium-sensitizing properties that increases myocardial contractile force without increasing intracellular calcium." | 6.40 | Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. ( Kubo, SH, 1997) |
| "Pimobendan is a novel cardiotonic vasodilator (inodilator) which derives its inotropic activity from a combination of phosphodiesterase III inhibition and sensitisation of myocardial contractile proteins to calcium." | 6.39 | Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. ( Brogden, RN; Fitton, A, 1994) |
| "In patients with chronic congestive heart failure, pimobendan produces a dose-dependent and prolonged decrease in pulmonary capillary wedge pressure and an increase in cardiac output." | 6.38 | Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. ( Hagemeijer, F, 1993) |
| "A knock-in mouse model of human genetic dilated cardiomyopathy, which shows a clear transition from compensatory to end-stage HF at a fixed time during growth, was used to evaluate the efficacy of pimobendan and explore the underlying molecular and cellular mechanisms." | 5.42 | Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. ( Arioka, M; Kurebayashi, N; Li, L; Morimoto, S; Murayama, T; Nonaka, M; Sasaguri, T; Takahashi-Yanaga, F; Wang, YY; Yoshihara, T, 2015) |
| "The benefits of pimobendan in the treatment of congestive heart failure (CHF) in cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively." | 5.41 | Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. ( Glaus, T; Lehmkuhl, L; Loureiro, J; Luis Fuentes, V; MacGregor, J; Mohren, N; Rush, JE; Sayer, MP; Schober, KE; Summerfield, NJ; Wess, G; Wright, K, 2021) |
| "Heart failure was induced in 20 dogs, to which pimobendan and two different doses of SCH00013 were administered orally to 15 dogs for 3 weeks, and the remaining 5 dogs served as the control." | 5.40 | Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing-induced model of heart failure. ( Fukayama, T; Fukushima, R; Hamabe, L; Kawamura, K; Kim, SM; Shimizu, M; Tanaka, R; Yoshiyuki, R, 2014) |
| "Triple therapy (TT) consisting of furosemide, pimobendan, and an angiotensin-converting enzyme inhibitor (ACEI) frequently is recommended for the treatment of congestive heart failure (CHF) attributable to myxomatous mitral valve disease (MMVD)." | 5.34 | Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial. ( Bauer, A; Gaugele, J; Glaus, T; Holler, P; Keller, L; Killich, M; Kresken, JG; Küchenhof, H; Simak, J; Wendt, R; Wess, G, 2020) |
| "Heart failure was induced by rapid ventricular pacing in 6 dogs instrumented with a micromanometer and a conductance catheter." | 5.29 | Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure. ( Asanoi, H; Ishise, H; Ishizaka, S; Kameyama, T; Sasayama, S, 1994) |
| "Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described." | 5.27 | Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Schummer, C; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2018) |
| "A fixed-dose combination tablet of benazepril and pimobendan (Fortekor Plus; Elanco Animal Health) was tested in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD) in a three-arm, masked, randomized, non-inferiority clinical trial in Japan." | 5.27 | Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial. ( Forster, S; Hirakawa, A; King, JN; Otaki, H; Sakakibara, N; Seewald, W; Sonobe, J, 2018) |
| "Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD)." | 5.22 | Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2016) |
| "No significant difference between pimobendan and placebo was found on incidence of supraventricular or ventricular arrhythmia." | 5.20 | Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. ( Griffiths, LG; Kass, PH; Lake-Bakaar, GA; Singh, MK, 2015) |
| "To evaluate the clinical efficacy and safety of pimobendan by comparing it with ramipril over a six-month period in dogs with mild to moderate heart failure (HF) caused by myxomatous mitral valve disease (MMVD)." | 5.11 | Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. ( Corcoran, BM; Dukes-McEwan, J; French, AT; Lee, AJ; Smith, PJ; Smith, SG; Swift, ST; Van Israël, N, 2005) |
| "The long-term beneficial effects of pimobendan in the treatment of chronic heart failure (CHF) have not been established, so the present trial compared pimobendan (1." | 5.10 | Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). ( , 2002) |
| "To evaluate the effects of the addition of pimobendan to an optimal basic regimen on plasma levels of neurohumoral factors in patients with non-ischemic, moderate heart failure during 2-year follow-up." | 5.09 | Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure. ( Komamura, K; Kubo, T; Nishikimi, T; Sasaki, T, 1999) |
| "Pimobendan improves exercise capacity in patients with chronic heart failure who are also on conventional treatment." | 5.08 | Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. ( Dumont, JM; Heinrich-Nols, J; Hjalmarsson, AC; Just, H; La Framboise, D; Lubsen, J; Remme, WJ; Seed, P, 1996) |
| "The results of Japanese studies on the clinical efficacy and safety of pimobendan in the treatment of heart failure are summarized in this paper." | 5.08 | Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan. ( Kato, K, 1997) |
| "The effects of pimobendan (UD-CG 115) on hemodynamics and exercise capacity after acute (single dose) and chronic (6 month) oral treatment, as well as acute treatment after 6 months were investigated in 67 patients with chronic heart failure of NYHA classes II or III, which had persisted in spite of treatment with diuretics and digitalis." | 5.07 | [Acute and long-term effects of pimobendan (UD-CG 115) in NYHA II and III heart failure. Results of a randomized multicenter double-blind study]. ( Assmann, I; Duck, HG; Fiehring, H; Höfs, T; Kassel, P; Morgan, P; Nehmiz, G; Schmidt, PK, 1991) |
| "In 25 patients whose chronic congestive heart failure (CHF) had recently worsened to New York Heart Association class IV, pimobendan (5 to 20 mg/day) was added to maximum conventional therapy consisting of digoxin, diuretics, angiotensin-converting enzyme inhibitors, coumadin derivatives to prevent thromboembolic complications, and amiodarone to suppress serious ventricular rhythm disturbances." | 5.07 | Intractable heart failure despite angiotensin-converting enzyme inhibitors, digoxin, and diuretics: long-term effectiveness of add-on therapy with pimobendan. ( Hagemeijer, F, 1991) |
| "In view of growing scepticism as to the efficacy and safety of agents with predominant phosphodiesterase inhibiting properties in heart failure, the clinical efficacy and safety of pimobendan, a calcium-sensitizing and partially phosphodiesterase-inhibiting compound, was compared with enalapril in 242 patients with mild to moderate heart failure (NYHA classification II-III) despite diuretics and digitalis, and abnormal haemodynamics at baseline." | 5.07 | Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group. ( Baiker, W; Baumann, G; Frick, MH; Haehl, M; Krayenbühl, HP; Nehmiz, G; Remme, WJ, 1994) |
| "Twenty-four patients (one female, 23 male) with mild to moderate heart failure were randomly and double-blindly assigned to an oral treatment with 5 mg enalapril twice daily or 5 mg pimobendan (UDCG 115) twice daily." | 5.07 | Comparison of hormonal and haemodynamic changes after long-term oral therapy with pimobendan or enalapril--a double-blind randomized study. ( Bleifeld, W; Erlemeier, HH; Kupper, W, 1991) |
| "In contrast to cyclic AMP-dependent positive inotropes, the calcium-sensitizer and partial phosphodiesterase (PDE) inhibitor pimobendan may induce beneficial effects in heart failure." | 5.07 | Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. ( Bartels, GL; de Leeuw, PW; Krauss, XH; Kruijssen, DA; Remme, WJ; Storm, CJ; van Hoogenhuyze, DC, 1994) |
| "To determine the reliability and validity of a patient outcome questionnaire for chronic heart failure, a randomized, double-blind, placebo-controlled, 3-month trial of pimobendan, an investigational medication with inotropic and vasodilator activities, was performed." | 5.07 | Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. ( Cohn, JN; Rector, TS, 1992) |
| "The long-term efficacy of the positive inotropic and vasodilator drug, pimobendan, was assessed in 21 patients suffering from symptomatic heart failure." | 5.07 | Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. ( Asanoi, H; Ejiri, M; Horikoshi, I; Kihara, Y; Sasayama, S; Terada, Y; Yokawa, S; Yoshida, S, 1994) |
| "These data demonstrate that pimobendan significantly increases exercise duration, peak VO2, and quality of life in patients with heart failure." | 5.07 | Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. ( Bourge, R; Brodsky, M; Brozena, S; Cobb, F; Gollub, S; Jessup, M; Kirlin, P; Kubo, SH; Rahko, P; Shanes, J, 1992) |
| "Acute hemodynamics of pimobendan were compared to captopril in a crossover trial in patients with chronic heart failure (NYHA II-III)." | 5.07 | Acute hemodynamics of pimobendan in chronic heart failure. A comparative crossover study of captopril and pimobendan. ( Aizaki, T; Hanawa, H; Izumi, T; Kodama, M; Kuwano, H; Shibata, A; Suzuki, M; Takahashi, M; Tsuda, T; Uchiyama, H, 1992) |
| " We compared the effects of two doses (5 and 10 mg) of oral pimobendane (UD-CG 115) on haemodynamics in eight patients suffering from chronic congestive heart failure." | 5.06 | Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses. ( Bernard, R; Dresse, A; Goethals, H; Liebens, I; Renard, M; Walter, M, 1988) |
| "Pimobendan is approved for use in dogs for the treatment of congestive heart failure (CHF) secondary to chronic valvular heart disease (CVHD) and dilated cardiomyopathy (DCM)." | 4.88 | A review of the pharmacology and clinical uses of pimobendan. ( Boyle, KL; Leech, E, 2012) |
| "Pimobendan is an oral inodilator compound available in many countries for use in canine heart failure." | 4.82 | Use of pimobendan in the management of heart failure. ( Fuentes, VL, 2004) |
| "Pimobendan is frequently used off-label for treatments of cats with congestive heart failure (CHF)." | 3.96 | Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy. ( DeFrancesco, TC; Keene, BW; Kussin, EZ; Tou, SP; Tropf, MA; Ward, JL, 2020) |
| "For study purposes, advanced heart failure was defined as recurrence of congestive heart failure signs despite receiving the initially prescribed dose of pimobendan, angiotensin-converting-enzyme inhibitor (ACEI), and furosemide >4 mg/kg/day." | 3.88 | Clinical findings and survival time in dogs with advanced heart failure. ( Beaumier, A; Freeman, LM; Rush, JE; Yang, VK, 2018) |
| "The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD)." | 3.85 | Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure. ( Chimura, S; Endo, M; Harada, K; Hirakawa, A; Maetani, S; Mizukoshi, T; Mizuno, M; Mizuno, T; Sawada, T; Shinoda, A; Takahashi, A; Takeuchi, J; Takusagawa, Y; Uchida, S; Uechi, M; Yamano, S, 2017) |
| "To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM)." | 3.80 | Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. ( Ames, MK; Atkins, CE; DeFrancesco, TC; Hodge, TE; Keene, BW; Meurs, KM; Reina-Doreste, Y; Stern, JA; Tou, SP, 2014) |
| " The patient was treated for congestive heart failure because of dilated cardiomyopathy with furosemide, enalapril, pimobendan and l-carnitine." | 3.80 | Diagnosis and treatment of congestive heart failure secondary to dilated cardiomyopathy in a hedgehog. ( Delk, KW; Eshar, D; Garcia, E; Harkin, K, 2014) |
| "We evaluated the effect of pimobendan, a positive inotropic agent, in elderly patients with frequent readmission as a result of heart failure despite conventional therapy." | 3.80 | Effect of pimobendan in addition to standard therapy for heart failure on prevention of readmission in elderly patients with severe chronic heart failure. ( Arakawa, S; Hayano, M; Kawano, H; Maemura, K; Matsumoto, Y; Nakatomi, D; Satoh, O; Yamasa, T, 2014) |
| "27 client-owned cats (16 male and 11 female) with heart failure, treated with pimobendan (mean ± SD dosage, 0." | 3.78 | Effect of oral administration of pimobendan in cats with heart failure. ( Achen, SE; Boggess, MM; Drourr, L; Fries, RC; Gordon, SG; Hariu, CD; Miller, MW; Roland, RM; Saunders, AB; Winter, RL, 2012) |
| "This retrospective study reports the survival time [onset of congestive heart failure (CHF) to death from any cause] of 21 dogs with mitral regurgitation (MR) and CHF treated with a combination of furosemide, angiotensin-converting enzyme inhibitor (ACEI, benazepril, or enalapril), pimobendan, spironolactone, and amlodipine." | 3.77 | Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases. ( de Madron, E; King, JN; Strehlau, G; White, RV, 2011) |
| "To describe the therapeutic use of pimobendan in cats, describe the patient population to which it was administered, document potential side effects and report the clinical course following administration of pimobendan in conjunction with standard heart failure therapy." | 3.77 | Use of pimobendan in 170 cats (2006-2010). ( Aronow, N; Cunningham, SM; Hall, DJ; Laste, NJ; Macgregor, JM; Malakoff, RL; Price, LL; Rush, JE; Williams, J, 2011) |
| " Using 6 conscious dogs with tachycardia-induced heart failure, the FFR was examined before and after administration of dobutamine (6 microg/kg/min) or pimobendan (0." | 3.71 | Disparate force-frequency effects of pimobendan and dobutamine in conscious dogs with tachycardia-induced cardiomyopathy. ( Asanoi, H; Inoue, H; Ishizaka, S; Joho, S; Kameyama, T, 2002) |
| "Pharmacokinetics and pharmacodynamics of pimobendan were studied in eight patients with dilated cardiomyopathy and chronic congestive heart failure after single dosing and after 2-week repeated dosing of 5 mg racemic pimobendan." | 3.69 | Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing. ( Chu, KM; Hu, OY; Shieh, SM, 1995) |
| "The acute systemic hemodynamic effects of the calcium antagonist nisoldipine and the pyridazinone-derivative pimobendan, a phosphodiesterase inhibitor with vasodilating as well as positive inotropic properties, were studied in conscious pigs with chronic heart failure." | 3.67 | Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure. ( Duncker, DJ; Roelandt, JR; van der Giessen, WJ; van Woerkens, LJ; Verdouw, PD, 1989) |
| "Pimobendan was administered orally (10 mg single dose on day 1, then 5 mg twice daily for 4 weeks) to nine patients with chronic heart failure undergoing hemodynamic monitoring." | 3.67 | Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure. ( Brand, HJ; Hagemeijer, F; Roth, W, 1989) |
| "Pimobendan (UD-CG 115 BS) was administered orally to 23 patients with congestive heart failure (functional class IV) caused by coronary artery disease (11 patients) or idiopathic dilated cardiomyopathy (12)." | 3.67 | Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Brand, HJ; Hagemeijer, F; van Mechelen, R, 1989) |
| "We studied the effects of oral administration of pimobendane on hemodynamics, blood gas levels, the renin-angiotensin system, and plasma catecholamines in 11 patients who were affected by severe chronic congestive heart failure." | 3.67 | Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent. ( Bernard, R; Dresse, A; Liebens, I; Renard, M; Walter, M, 1988) |
| "Pimobendan (10 mg on day 1, then 5 mg twice daily for 28 days) was administered orally to nine patients in class III-IV stable congestive heart failure." | 3.67 | Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing. ( Brand, HJ; Hagemeijer, F; Roth, W, 1989) |
| "Pimobendan is a positive inotropic agent with additional calcium-sensitizing effects of the phosphodiesterase III-inhibitor group." | 2.67 | [Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure]. ( Bergler-Klein, J; Globits, S; Glogar, D; Mayr, H; Porenta, G; Sochor, H; Stefenelli, T, 1992) |
| " Classic inotropic agents (beta-adrenergic agonists and phosphodiesterase III inhibitors) can provide short-term hemodynamic benefits, but their long-term use has been correlated with poor survival rates." | 2.43 | Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure. ( Kaplinsky, EJ; Perrone, SV, 2005) |
| "Levosimendan is a calcium sensitizer with no major inhibition of PDE at clinically relevant doses." | 2.42 | The role of Ca++-sensitizers for the treatment of heart failure. ( Boldt, J; Kirchner, J; Lehmann, A, 2003) |
| "Pimobendan is a benzimidazole-pyridazinone derivative with calcium-sensitizing properties that increases myocardial contractile force without increasing intracellular calcium." | 2.40 | Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. ( Kubo, SH, 1997) |
| "Pimobendan is a novel cardiotonic vasodilator (inodilator) which derives its inotropic activity from a combination of phosphodiesterase III inhibition and sensitisation of myocardial contractile proteins to calcium." | 2.39 | Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. ( Brogden, RN; Fitton, A, 1994) |
| "In patients with chronic congestive heart failure, pimobendan produces a dose-dependent and prolonged decrease in pulmonary capillary wedge pressure and an increase in cardiac output." | 2.38 | Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. ( Hagemeijer, F, 1993) |
| "In dogs with canine monocytic ehrlichiosis (CME), respiratory signs are uncommon and clinical and radiographic signs of interstitial pneumonia are poorly described." | 1.43 | Interstitial pneumonia and pulmonary hypertension associated with suspected ehrlichiosis in a dog. ( Broens, EM; Dobak, TP; Toom, ML; Valtolina, C, 2016) |
| "A knock-in mouse model of human genetic dilated cardiomyopathy, which shows a clear transition from compensatory to end-stage HF at a fixed time during growth, was used to evaluate the efficacy of pimobendan and explore the underlying molecular and cellular mechanisms." | 1.42 | Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. ( Arioka, M; Kurebayashi, N; Li, L; Morimoto, S; Murayama, T; Nonaka, M; Sasaguri, T; Takahashi-Yanaga, F; Wang, YY; Yoshihara, T, 2015) |
| "Heart failure was induced in 20 dogs, to which pimobendan and two different doses of SCH00013 were administered orally to 15 dogs for 3 weeks, and the remaining 5 dogs served as the control." | 1.40 | Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing-induced model of heart failure. ( Fukayama, T; Fukushima, R; Hamabe, L; Kawamura, K; Kim, SM; Shimizu, M; Tanaka, R; Yoshiyuki, R, 2014) |
| "Heart failure is associated with pathobiochemical changes that can reduce the responsiveness of the myocardium to positive inotropic agents." | 1.30 | The effect of positive inotropes on the failing human myocardium. ( Erdmann, E, 1997) |
| "Heart failure was induced by rapid ventricular pacing in 6 dogs instrumented with a micromanometer and a conductance catheter." | 1.29 | Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure. ( Asanoi, H; Ishise, H; Ishizaka, S; Kameyama, T; Sasayama, S, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (14.29) | 18.7374 |
| 1990's | 35 (33.33) | 18.2507 |
| 2000's | 27 (25.71) | 29.6817 |
| 2010's | 24 (22.86) | 24.3611 |
| 2020's | 4 (3.81) | 2.80 |
| Authors | Studies |
|---|---|
| Erhardt, PW | 1 |
| Okamoto, N | 1 |
| Kubo, T | 2 |
| Nakashima, Y | 1 |
| Ochi, Y | 1 |
| Takahashi, A | 2 |
| Baba, Y | 1 |
| Hirota, T | 1 |
| Yamasaki, N | 1 |
| Kitaoka, H | 1 |
| Wess, G | 4 |
| Kresken, JG | 3 |
| Wendt, R | 1 |
| Gaugele, J | 1 |
| Killich, M | 1 |
| Keller, L | 1 |
| Simak, J | 1 |
| Holler, P | 1 |
| Bauer, A | 1 |
| Küchenhof, H | 1 |
| Glaus, T | 2 |
| Ward, JL | 1 |
| Kussin, EZ | 1 |
| Tropf, MA | 1 |
| Tou, SP | 2 |
| DeFrancesco, TC | 2 |
| Keene, BW | 4 |
| Schober, KE | 1 |
| Rush, JE | 3 |
| Luis Fuentes, V | 1 |
| Summerfield, NJ | 1 |
| Wright, K | 1 |
| Lehmkuhl, L | 1 |
| Sayer, MP | 1 |
| Loureiro, J | 1 |
| MacGregor, J | 1 |
| Mohren, N | 1 |
| King, JN | 2 |
| Hirakawa, A | 2 |
| Sonobe, J | 1 |
| Otaki, H | 1 |
| Sakakibara, N | 1 |
| Seewald, W | 1 |
| Forster, S | 1 |
| Boswood, A | 3 |
| Gordon, SG | 3 |
| Häggström, J | 2 |
| Stepien, RL | 2 |
| Oyama, MA | 3 |
| Bonagura, J | 2 |
| MacDonald, KA | 2 |
| Patteson, M | 3 |
| Smith, S | 3 |
| Fox, PR | 2 |
| Sanderson, K | 2 |
| Woolley, R | 2 |
| Szatmári, V | 2 |
| Menaut, P | 2 |
| Church, WM | 2 |
| O'Sullivan, ML | 2 |
| Jaudon, JP | 2 |
| Rush, J | 2 |
| Barrett, KA | 2 |
| Rosenthal, SL | 2 |
| Saunders, AB | 3 |
| Ljungvall, I | 2 |
| Deinert, M | 2 |
| Bomassi, E | 2 |
| Estrada, AH | 2 |
| Fernandez Del Palacio, MJ | 2 |
| Moise, NS | 3 |
| Abbott, JA | 2 |
| Fujii, Y | 2 |
| Spier, A | 2 |
| Luethy, MW | 2 |
| Santilli, RA | 2 |
| Uechi, M | 3 |
| Tidholm, A | 2 |
| Schummer, C | 1 |
| Watson, P | 2 |
| Beaumier, A | 1 |
| Yang, VK | 1 |
| Freeman, LM | 1 |
| Hezzell, MJ | 1 |
| Block, CL | 1 |
| Laughlin, DS | 1 |
| Kawano, H | 1 |
| Arakawa, S | 1 |
| Satoh, O | 1 |
| Matsumoto, Y | 1 |
| Hayano, M | 1 |
| Nakatomi, D | 1 |
| Yamasa, T | 1 |
| Maemura, K | 1 |
| Murai, K | 1 |
| Seino, Y | 1 |
| Kimata, N | 1 |
| Inami, T | 1 |
| Murakami, D | 1 |
| Abe, J | 1 |
| Yodogawa, K | 1 |
| Maruyama, M | 1 |
| Takano, M | 1 |
| Ohba, T | 1 |
| Ibuki, C | 1 |
| Mizuno, K | 1 |
| Wainberg, S | 1 |
| Delk, KW | 1 |
| Eshar, D | 1 |
| Garcia, E | 1 |
| Harkin, K | 1 |
| Hamabe, L | 1 |
| Kawamura, K | 1 |
| Kim, SM | 1 |
| Yoshiyuki, R | 1 |
| Fukayama, T | 1 |
| Shimizu, M | 1 |
| Fukushima, R | 1 |
| Tanaka, R | 1 |
| Reina-Doreste, Y | 1 |
| Stern, JA | 1 |
| Atkins, CE | 1 |
| Ames, MK | 1 |
| Hodge, TE | 1 |
| Meurs, KM | 1 |
| Nonaka, M | 1 |
| Morimoto, S | 1 |
| Murayama, T | 1 |
| Kurebayashi, N | 1 |
| Li, L | 1 |
| Wang, YY | 1 |
| Arioka, M | 1 |
| Yoshihara, T | 1 |
| Takahashi-Yanaga, F | 1 |
| Sasaguri, T | 1 |
| McNaughton, A | 1 |
| Frasca, S | 1 |
| Mishra, N | 1 |
| Tuttle, AD | 1 |
| Lake-Bakaar, GA | 1 |
| Singh, MK | 1 |
| Kass, PH | 1 |
| Griffiths, LG | 1 |
| Toom, ML | 1 |
| Dobak, TP | 1 |
| Broens, EM | 1 |
| Valtolina, C | 1 |
| Mizuno, M | 1 |
| Yamano, S | 1 |
| Chimura, S | 1 |
| Takusagawa, Y | 1 |
| Sawada, T | 1 |
| Maetani, S | 1 |
| Mizuno, T | 1 |
| Harada, K | 1 |
| Shinoda, A | 1 |
| Uchida, S | 1 |
| Takeuchi, J | 1 |
| Mizukoshi, T | 1 |
| Endo, M | 1 |
| Dukes-McEwan, J | 2 |
| French, A | 1 |
| Little, C | 1 |
| Swift, S | 1 |
| Willis, R | 1 |
| Endoh, M | 2 |
| Macgregor, JM | 1 |
| Laste, NJ | 1 |
| Malakoff, RL | 1 |
| Cunningham, SM | 1 |
| Aronow, N | 1 |
| Hall, DJ | 1 |
| Williams, J | 1 |
| Price, LL | 1 |
| Bowles, D | 1 |
| Fry, D | 1 |
| de Madron, E | 1 |
| Strehlau, G | 1 |
| White, RV | 1 |
| Roland, RM | 1 |
| Winter, RL | 1 |
| Drourr, L | 1 |
| Achen, SE | 1 |
| Hariu, CD | 1 |
| Fries, RC | 1 |
| Boggess, MM | 1 |
| Miller, MW | 1 |
| Arai, M | 1 |
| Caivano, D | 1 |
| Birettoni, F | 1 |
| Fruganti, A | 1 |
| Rishniw, M | 1 |
| Knafelz, P | 1 |
| Porciello, F | 1 |
| Boyle, KL | 1 |
| Leech, E | 1 |
| Sasayama, S | 6 |
| Takeda, N | 1 |
| Ohtaki, E | 1 |
| Misu, K | 1 |
| Asano, R | 1 |
| Tobaru, T | 1 |
| Nagayama, M | 1 |
| Kitahara, K | 1 |
| Umemura, J | 1 |
| Sumiyoshi, T | 1 |
| Hosoda, S | 1 |
| Joho, S | 1 |
| Asanoi, H | 4 |
| Ishizaka, S | 2 |
| Kameyama, T | 2 |
| Inoue, H | 2 |
| Kohno, M | 1 |
| Matsumori, A | 3 |
| Lehmann, A | 1 |
| Boldt, J | 1 |
| Kirchner, J | 1 |
| Butson, R | 1 |
| Wakaumi, M | 1 |
| Shiga, T | 2 |
| Naganuma, M | 2 |
| Matsuda, N | 2 |
| Tatami, S | 1 |
| Kasanuki, H | 2 |
| Watanabe, E | 1 |
| Kajimoto, K | 1 |
| Kawai, A | 1 |
| Fuentes, VL | 1 |
| Smith, PJ | 1 |
| French, AT | 1 |
| Van Israël, N | 1 |
| Smith, SG | 1 |
| Swift, ST | 1 |
| Lee, AJ | 1 |
| Corcoran, BM | 1 |
| Schwinger, RH | 2 |
| Brixius, K | 2 |
| Perrone, SV | 1 |
| Kaplinsky, EJ | 1 |
| Hoyer, HK | 1 |
| Ferasin, L | 1 |
| Marcora, S | 1 |
| Shinagawa, H | 1 |
| Izumi, T | 4 |
| Iwama, Y | 1 |
| Takagi, A | 1 |
| Ishise, H | 1 |
| Hagemeijer, F | 6 |
| Remme, WJ | 3 |
| Kruijssen, DA | 1 |
| van Hoogenhuyze, DC | 1 |
| Krauss, XH | 1 |
| Bartels, GL | 1 |
| Storm, CJ | 1 |
| de Leeuw, PW | 1 |
| Chu, KM | 1 |
| Shieh, SM | 1 |
| Hu, OY | 1 |
| Krayenbühl, HP | 1 |
| Baumann, G | 4 |
| Frick, MH | 1 |
| Haehl, M | 1 |
| Nehmiz, G | 2 |
| Baiker, W | 1 |
| Fitton, A | 1 |
| Brogden, RN | 1 |
| Kihara, Y | 1 |
| Yokawa, S | 1 |
| Terada, Y | 1 |
| Yoshida, S | 1 |
| Ejiri, M | 1 |
| Horikoshi, I | 1 |
| Kubo, SH | 4 |
| Satoh, K | 1 |
| Satoh, Y | 1 |
| Imagawa, J | 1 |
| Taira, N | 1 |
| Lubsen, J | 1 |
| Just, H | 1 |
| Hjalmarsson, AC | 1 |
| La Framboise, D | 1 |
| Heinrich-Nols, J | 1 |
| Dumont, JM | 1 |
| Seed, P | 1 |
| Ono, K | 1 |
| Sato, Y | 1 |
| Shioi, T | 1 |
| Nose, Y | 1 |
| Shiraishi, M | 1 |
| Murayama, K | 1 |
| Hanzawa, K | 1 |
| Warabi, K | 1 |
| Kamiyama, Y | 1 |
| Erdmann, E | 1 |
| Holubarsch, C | 1 |
| Kato, K | 1 |
| Ohte, N | 1 |
| Cheng, CP | 1 |
| Suzuki, M | 4 |
| Little, WC | 1 |
| Mathew, L | 1 |
| Katz, SD | 2 |
| Sasaki, T | 1 |
| Komamura, K | 1 |
| Nishikimi, T | 1 |
| Matsumoto, A | 1 |
| Momomura, S | 1 |
| Yokoyama, I | 1 |
| Aoyagi, T | 1 |
| Sugiura, S | 1 |
| Omata, M | 1 |
| Ishiki, R | 1 |
| Ishihara, T | 1 |
| Izawa, H | 1 |
| Nagata, K | 1 |
| Hirai, M | 1 |
| Yokota, M | 1 |
| Yoshikawa, T | 1 |
| Baba, A | 1 |
| Yokozuka, H | 1 |
| Okada, Y | 1 |
| Nagami, K | 1 |
| Takahashi, T | 1 |
| Mitamura, H | 1 |
| Ogawa, S | 1 |
| Ako, J | 1 |
| Eto, M | 1 |
| Watanabe, T | 1 |
| Ouchi, Y | 1 |
| Chin, BS | 1 |
| Lip, GY | 1 |
| Tsuda, T | 3 |
| Kodama, M | 3 |
| Hanawa, H | 2 |
| Ohshima, M | 1 |
| Takahashi, M | 2 |
| Aizaki, T | 2 |
| Uchiyama, H | 2 |
| Shibata, A | 3 |
| Fujita, T | 1 |
| Nonaka, R | 1 |
| Miyajima, T | 1 |
| Tanaka, Y | 1 |
| Bergler-Klein, J | 2 |
| Globits, S | 2 |
| Stefenelli, T | 2 |
| Mayr, H | 1 |
| Porenta, G | 1 |
| Sochor, H | 1 |
| Glogar, D | 2 |
| Rector, TS | 1 |
| Cohn, JN | 2 |
| Gollub, S | 1 |
| Bourge, R | 1 |
| Rahko, P | 1 |
| Cobb, F | 1 |
| Jessup, M | 2 |
| Brozena, S | 2 |
| Brodsky, M | 1 |
| Kirlin, P | 1 |
| Shanes, J | 1 |
| Kuwano, H | 1 |
| Pacher, R | 1 |
| Troha, JM | 1 |
| Wahl, J | 1 |
| Sonnenblick, EH | 1 |
| LeJemtel, TH | 1 |
| Assmann, I | 1 |
| Kassel, P | 1 |
| Duck, HG | 1 |
| Fiehring, H | 1 |
| Morgan, P | 1 |
| Schmidt, PK | 1 |
| Höfs, T | 1 |
| Erlemeier, HH | 1 |
| Kupper, W | 1 |
| Bleifeld, W | 1 |
| Thierfelder, L | 1 |
| Holubarsch, CH | 1 |
| Hasenfuss, G | 1 |
| Just, HJ | 1 |
| Colucci, WS | 1 |
| Wright, RF | 1 |
| Braunwald, E | 1 |
| Ningel, K | 2 |
| Permanetter, B | 3 |
| Brand, HJ | 3 |
| Roth, W | 2 |
| van der Giessen, WJ | 1 |
| van Woerkens, LJ | 1 |
| Duncker, DJ | 2 |
| Roelandt, JR | 1 |
| Verdouw, PD | 2 |
| Pouleur, H | 1 |
| Hanet, C | 1 |
| Schröder, E | 1 |
| Col, J | 1 |
| Van Mechelen, H | 1 |
| Etienne, J | 1 |
| Rousseau, MF | 1 |
| Hauf, GF | 1 |
| Grom, E | 1 |
| Jähnchen, E | 1 |
| Roskamm, H | 1 |
| Wirtzfeld, A | 1 |
| Günes, S | 1 |
| Stinshoff, M | 1 |
| Klein, G | 1 |
| van Mechelen, R | 1 |
| van Dalen, FJ | 1 |
| Hartog, JM | 1 |
| Lamers, JM | 1 |
| Rensen, RJ | 1 |
| Saxena, PR | 1 |
| Walter, M | 2 |
| Liebens, I | 2 |
| Goethals, H | 1 |
| Renard, M | 2 |
| Dresse, A | 2 |
| Bernard, R | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tunneled Pleural Catheters for Refractory Effusions Attributed to Congestive Heart Failure (TREAT-CHF) Trial[NCT03696524] | 0 participants (Actual) | Interventional | 2020-10-01 | Withdrawn (stopped due to Lack of enrollment) | |||
| Effects of a Multimedia Symptom Management Program on Coping Strategies, Symptom Distress, Depressive Status, and Quality of Life in Patients With Heart Failure: A Randomized Controlled Trial[NCT04715490] | 78 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial[NCT03004703] | Phase 2 | 200 participants (Actual) | Interventional | 2017-03-16 | Completed | ||
| Effects of Identifying and Treating Early, Subclinical Cardiotoxicity on the Long-Term Incidence of Clinical Cardiotoxicity in Women With Breast Cancer, A Prospective Randomized Study: The Cardio-Oncology Breast Cancer Study (COBC)[NCT02571894] | 320 participants (Anticipated) | Interventional | 2014-07-31 | Active, not recruiting | |||
| An Examination of Palliative Care as Standard Practice for Heart Failure Patients[NCT01519479] | 232 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| Effects of a Walking Program and Inspiratory Muscle Training in Individuals With Chronic Heart Failure - A Pilot Study[NCT01560871] | 16 participants (Actual) | Interventional | 2012-03-31 | Completed | |||
| Evaluation of the Six Minute Walk Test, Heart Rate Variability and Quality of Life in Heart Failure Patients on Beta-blocker Treatment[NCT01736137] | 17 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This questionnaire includes 21 questions which ask how much the heart condition affected the patient's life during the past month. Each question has 5 optional answers with the scores ranging from 0 to 5. A higher score indicates a worse outcome. The minimum overall score of the questionnaire is 0 and the maximum score is 105. A higher overall score on the Minnesota Living with Heart Failure Questionnaire indicates a worse outcome. (NCT01560871)
Timeframe: Baseline and 6 weeks
| Intervention | score on a scale (Mean) | |
|---|---|---|
| MLHF score at baseline | change from baseline at 6 weeks | |
| High-intensity IMT Plus Walking | 57.6 | -20.6 |
| Low-intensity IMT Plus Walking | 36 | 18.6 |
The SF-36 quality of life questionnaire (short form) was used. A higher score of the SF-36 questionnaire indicates a better outcome (i.e., lower disability). The range of overall score on the SF-36 questionnaire is from 0 to 100. (NCT01560871)
Timeframe: Baseline and 6 weeks
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline Physical SF-36 | Change from baseline physical SF-36 | |
| High-intensity IMT Plus Walking | 30.7 | 7.08 |
| Low-intensity IMT Plus Walking | 34.1 | 0.82 |
Each subject was given a pedometer to record his/her step counts every day. (NCT01560871)
Timeframe: Baseline and 6 weeks
| Intervention | steps/day (Mean) | |
|---|---|---|
| Baseline daily step count at Week 1 | Daily step counts at week 6 | |
| High-intensity IMT Plus Walking | 7002 | 9255 |
| Low-intensity IMT Plus Walking | 3512 | 4434 |
The inspiratory muscle strength will be measured in the unit of cmH2O by the Respiratory Muscle Pressure Meter (Micro Direct). A higher inspiratory pressure indicates a better inspiratory breathing strength. (NCT01560871)
Timeframe: Baseline and 6 weeks
| Intervention | cm H2O (Mean) | |
|---|---|---|
| Baseline PImax at week 1 | PImax at week 6 | |
| High-intensity IMT Plus Walking | 43.53 | 58.13 |
| Low-intensity IMT Plus Walking | 51.44 | 57.22 |
The six-minute walk test is a measure of cardiovascular endurance which measures how far a person can walk in 6 minutes. This test was conducted twice respectively at pre-training and at post-training to account for potential learning effect. A longer distance walked on the six-minute walking test indicates a better cardiovascular endurance. (NCT01560871)
Timeframe: Baseline and 6 Weeks
| Intervention | meters (Mean) | |
|---|---|---|
| six-minute walk distance at week 1 | Six-minute walk distance at week 6 | |
| High-intensity IMT Plus Walking | 378.04 | 419.71 |
| Low-intensity IMT Plus Walking | 356.16 | 375.78 |
25 reviews available for pimobendan and Cardiac Failure
| Article | Year |
|---|---|
In search of the digitalis replacement.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Cyclic AMP; Digitalis Glycosides; Heart Fai | 1987 |
Cardiac Ca2+ signaling and Ca2+ sensitizers.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Angiotensin II; Animals; Azocines; Calcium; Cal | 2008 |
Pimobendan and its use in treating canine congestive heart failure.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Heart Failure; Pyridazines; Treatment Outcome | 2011 |
[Calcium mobilizers and calcium sensitizers].
Topics: Calcium; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Pyridazines; | 2011 |
A review of the pharmacology and clinical uses of pimobendan.
Topics: Animals; Cardiotonic Agents; Heart Failure; Pyridazines | 2012 |
[Pharmacological treatment of heart failure].
Topics: Acute Disease; Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotensi | 2003 |
[Roles of cytokines in the pathogenesis of heart failure].
Topics: Animals; Antibodies, Monoclonal; Cytokines; Disease Models, Animal; Genetic Therapy; Heart Failure; | 2003 |
[Inotropic agents].
Topics: Adrenergic alpha-Agonists; Animals; Cardiotonic Agents; Clinical Trials as Topic; Digitalis Glycosid | 2003 |
The role of Ca++-sensitizers for the treatment of heart failure.
Topics: Calcium; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dobutamine; Heart Failure; H | 2003 |
Use of pimobendan in the management of heart failure.
Topics: Animals; Cardiotonic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Heart Failure; Phosphodiesteras | 2004 |
[Cytokine antagonists and endothelin antagonists for therapy of heart failure].
Topics: Angiotensin II; Animals; Antibodies, Monoclonal; Bosentan; Clinical Trials as Topic; Cytokines; Endo | 2005 |
[If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency].
Topics: Actin Cytoskeleton; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydrazones; Myocardiu | 2005 |
Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
Topics: Arrhythmias, Cardiac; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2005 |
Ca2+-sensitisers--a promising option to treat heart failure?
Topics: Calcium; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2005 |
[Calcium sensitizer: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Calcium; Cardiotonic Agents; Clinical Trials as Topic; Contraindications; Heart Failure; Humans; Hyd | 2007 |
[Calcium sensitizer agents in heart failure therapy].
Topics: Calcium; Cardiotonic Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Myocardial | 2007 |
Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Clinical Trials as Topic; Drug Interactions; Elec | 1994 |
Inotropic agents with calcium-sensitizing properties: clinical and hemodynamic effects of pimobendan.
Topics: Animals; Calcium; Cardiotonic Agents; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans; | 1994 |
Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure.
Topics: Animals; Calcium; Death, Sudden, Cardiac; Heart Failure; Hemodynamics; Humans; Myocardial Contractio | 1993 |
Inotropic agents in the treatment of heart failure: despair or hope?
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Cyclic AMP; Digitalis; Heart Failure; Humans; Plants, | 1997 |
Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure.
Topics: Cardiotonic Agents; Exercise Tolerance; Heart Failure; Humans; Pyridazines; Quality of Life; Randomi | 1997 |
Calcium sensitising agents in heart failure.
Topics: Aged; Animals; Calcium; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 1998 |
[Ca2+ sensitizers].
Topics: Animals; Calcium; Cardiotonic Agents; Cyclic AMP; Dihydropyridines; Drug Design; Heart Failure; Huma | 2000 |
New pharmacological strategies for the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atrial Natriuretic Factor; Bosentan; Calcium; | 2001 |
New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1986 |
32 trials available for pimobendan and Cardiac Failure
48 other studies available for pimobendan and Cardiac Failure
| Article | Year |
|---|---|
Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis.
Topics: Aged; Aged, 80 and over; Amyloid; Amyloid Neuropathies, Familial; Cardiotonic Agents; Female; Heart | 2020 |
Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy.
Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Cat Diseases; Cats; Heart Failure; Pyridazines; Retro | 2020 |
Clinical findings and survival time in dogs with advanced heart failure.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Furosemide; Heart Failure; Male; Mitral Val | 2018 |
What Is Your Diagnosis?
Topics: Animals; Atherosclerosis; Bird Diseases; Cardiotonic Agents; Diagnosis, Differential; Diuretics; Ech | 2018 |
Effect of pimobendan in addition to standard therapy for heart failure on prevention of readmission in elderly patients with severe chronic heart failure.
Topics: Aged; Aged, 80 and over; Biomarkers; Cardiotonic Agents; Disease Progression; Dose-Response Relation | 2014 |
Efficacy and limitations of oral inotropic agents for the treatment of chronic heart failure.
Topics: Administration, Oral; Aged; Aged, 80 and over; Cardiotonic Agents; Chronic Disease; Cross-Sectional | 2013 |
Use of pimobendan in feline congenital heart failure.
Topics: Animals; Cardiotonic Agents; Cat Diseases; Cats; Female; Heart Failure; Pyridazines; Tricuspid Valve | 2013 |
Diagnosis and treatment of congestive heart failure secondary to dilated cardiomyopathy in a hedgehog.
Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Carnitine; Drug Therapy, Combination; Heart Fa | 2014 |
Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing-induced model of heart failure.
Topics: Administration, Oral; Animals; Calcium; Cardiotonic Agents; Dihydropyridines; Dilatation, Pathologic | 2014 |
Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure.
Topics: Animals; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Case-Control Studies; Cat Diseases; Cats; | 2014 |
Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure.
Topics: Animals; Calcium Channels, L-Type; Calcium Signaling; Cardiomyopathy, Dilated; Cardiotonic Agents; D | 2015 |
Valvular dysplasia and congestive heart failure in a juvenile African penguin (Spheniscus demersus).
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Zoo; Bird Diseases; Cardiotonic Agents; | 2014 |
Interstitial pneumonia and pulmonary hypertension associated with suspected ehrlichiosis in a dog.
Topics: Animals; Antiparasitic Agents; Dog Diseases; Dogs; Doxycycline; Ehrlichiosis; Heart Failure; Hyperte | 2016 |
Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Failure; Male; Mitral Valve Insuffici | 2017 |
Treatment of congestive heart failure in dogs.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Heart Failure; Pyridazines; Randomized Controlled T | 2008 |
Use of pimobendan in 170 cats (2006-2010).
Topics: Animals; Cardiotonic Agents; Cat Diseases; Cats; Dose-Response Relationship, Drug; Female; Follow-Up | 2011 |
Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiotonic Agents; Death, Sudden, | 2011 |
Effect of oral administration of pimobendan in cats with heart failure.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Cat Diseases; Cats; Cohort Studies; Female; Heart | 2012 |
Transthoracic echocardiographically-guided interventional cardiac procedures in the dog.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Balloon Valvuloplasty; Benzazepines; Cardiotonic | 2012 |
Inotropic agents and immune modulation.
Topics: Adjuvants, Immunologic; Animals; Cardiotonic Agents; Clinical Trials as Topic; Cytokines; Heart Fail | 2002 |
Normalization of left ventricular parameters following combined pimobendan and carvedilol treatment in a case of unclassified cardiomyopathy with longstanding refractory status.
Topics: Carbazoles; Cardiomyopathies; Cardiovascular Agents; Carvedilol; Heart Failure; Humans; Male; Middle | 2002 |
Disparate force-frequency effects of pimobendan and dobutamine in conscious dogs with tachycardia-induced cardiomyopathy.
Topics: Adrenergic beta-Agonists; Animals; Cardiac Pacing, Artificial; Cardiotonic Agents; Dobutamine; Dogs; | 2002 |
Treatment of congestive heart failure.
Topics: Animals; Cardiotonic Agents; Data Interpretation, Statistical; Dog Diseases; Dogs; Heart Failure; Py | 2003 |
Low-dose systemic phosphodiesterase III inhibitor pimobendan combined with prostacyclin therapy in a patient with severe primary pulmonary hypertension.
Topics: Adult; Drug Therapy, Combination; Epoprostenol; Female; Heart Failure; Humans; Hypertension, Pulmona | 2003 |
A pilot study to assess the feasibility of a submaximal exercise test to measure individual response to cardiac medication in dogs with acquired heart failure.
Topics: Animals; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Cardiotonic Agents; Dog Disease | 2007 |
Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure.
Topics: Animals; Cardiac Catheterization; Cardiotonic Agents; Diastole; Dogs; Electric Stimulation; Electrop | 1994 |
Hemodynamic performance during exercise in patients with severe chronic congestive heart failure before and after a single dose of pimobendan.
Topics: Administration, Oral; Aged; Cardiomyopathy, Dilated; Cardiotonic Agents; Child; Exercise; Female; He | 1994 |
Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
Topics: Administration, Oral; Analysis of Variance; Cardiomyopathy, Dilated; Cardiotonic Agents; Echocardiog | 1995 |
Improvement of cardiac performance by pimobendan, a new cardiotonic drug, in the experimental failing dog heart.
Topics: Animals; Cardiotonic Agents; Dogs; Dose-Response Relationship, Drug; Female; Heart; Heart Failure; M | 1993 |
Positive inotropic agents: a double-edged sword for chronic heart failure.
Topics: Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hea | 1996 |
Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzy | 1996 |
[Epidural anesthesia for herniorrhaphy in a patient with severe dilated cardiomyopathy (DCM) under pimobendan control].
Topics: Anesthesia, Epidural; Cardiomyopathy, Dilated; Cardiotonic Agents; Dobutamine; Dopamine; Fentanyl; H | 1997 |
The effect of positive inotropes on the failing human myocardium.
Topics: 1-Methyl-3-isobutylxanthine; Adrenergic beta-Agonists; Calcium; Cardiotonic Agents; Dobutamine; Hear | 1997 |
New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors.
Topics: Animals; Calcium; Cardiotonic Agents; Deoxyepinephrine; Energy Metabolism; Guinea Pigs; Heart Failur | 1997 |
The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure.
Topics: Amrinone; Animals; Dogs; Heart Failure; Phosphodiesterase Inhibitors; Physical Conditioning, Animal; | 1997 |
A case of severe hypoglycemia due to pimobendan.
Topics: Aged; Cardiotonic Agents; Heart Failure; Humans; Hypoglycemia; Male; Pyridazines | 2001 |
[Acute hemodynamic effects of pimobendan and captopril: a comparative study in the same patients with chronic heart failure].
Topics: Aged; Captopril; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pyridazines; Vasodi | 1992 |
[A case of dilated cardiomyopathy with intractable heart failure treated with adjunctive therapy of pimobendan and denopamine].
Topics: Cardiomyopathy, Dilated; Chemotherapy, Adjuvant; Ethanolamines; Furosemide; Heart Failure; Humans; I | 1992 |
Heart rate behaviour at different stages of congestive heart failure.
Topics: Adult; Aged; Cardiotonic Agents; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; | 1992 |
Myocardial energetics in dilated cardiomyopathy.
Topics: Adrenergic beta-Agonists; Cardiac Output; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Circ | 1990 |
Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing.
Topics: Aged; Blood Chemical Analysis; Blood Pressure; Cardiac Output; Cardiotonic Agents; Exercise Test; Fe | 1989 |
Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure.
Topics: Acid-Base Equilibrium; Animals; Blood Gas Analysis; Chronic Disease; Heart Failure; Hemodynamics; Ni | 1989 |
Pharmacotherapy of congestive heart failure: pimobendan, a new approach to inotropic stimulation. Proceedings of a satellite symposium to the Xth European Congress of Cardiology. Vienna, Austria, August 31, 1988.
Topics: Animals; Cardiotonic Agents; Heart Failure; Humans; Pyridazines | 1989 |
Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure.
Topics: Animals; Cardiac Output, Low; Cardiotonic Agents; Dogs; Heart Failure; Heart Ventricles; Hemodynamic | 1989 |
Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure.
Topics: Administration, Oral; Aged; Cardiotonic Agents; Cardiovascular System; Female; Heart Failure; Hemody | 1989 |
Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Topics: Administration, Oral; Aged; Cardiomyopathy, Dilated; Coronary Disease; Female; Heart Failure; Hemody | 1989 |
Usefulness of pimobendan in the treatment of heart failure.
Topics: Animals; Cardiac Output; Cardiotonic Agents; Cyclic AMP; Cyclic GMP; Heart Failure; Myocardial Contr | 1986 |
Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent.
Topics: Administration, Oral; Aged; Cardiotonic Agents; Chromatography, High Pressure Liquid; Epinephrine; F | 1988 |